# Moderna (MRNA) Financial Model

Free Excel 3-statement financial model and company analysis for Moderna.

- Canonical: https://finamodel.com/companies/moderna
- Industry: Pharmaceuticals
- Downloadable model: Yes
- Excel download: https://finamodel.com/company-models/MRNA.xlsx

## Model Purpose

This model evaluates Moderna's cash runway and equity valuation to determine if the company can successfully bridge the gap to its stated 2028 cash-flow breakeven target without requiring highly dilutive equity financing.

## Company Overview

Moderna is a pioneering biotechnology company that develops messenger RNA (mRNA) therapeutics and vaccines. The company historically generated unprecedented cash flows from its COVID-19 vaccine (Spikevax) but is currently transitioning into a broader respiratory and oncology business.

Business segments consist primarily of a single reportable segment, but revenue is broken down into Product Sales (Spikevax and the newly launched RSV vaccine, mRESVIA) and Grant/Collaboration Revenue. The geographic split is shifting, with management targeting a 50/50 split between the US and international markets by 2026. Moderna operates a hybrid manufacturing model, utilising internal facilities in Massachusetts alongside significant third-party contract manufacturing organisation (CMO) partnerships. Its competitive position is strong in the mRNA space, forming a duopoly with BioNTech/Pfizer in COVID-19, though it faces intense competition in the RSV and seasonal flu markets from GSK, Pfizer, and Sanofi. Recent major events include a massive post-pandemic revenue contraction (from $19 billion in 2022 to $1.9 billion in 2025), the launch of mRESVIA, an FDA refusal-to-file for its flu candidate (mRNA-1010), and a severe cost-restructuring programme aimed at reducing operating expenses by over $2 billion.

## Revenue Deep Dive



### Product Sales: Spikevax (COVID-19)

- **Segment name**: Net Product Sales - Spikevax
- **Revenue driver formula**: (US Doses Administered x Market Share x Net Price per Dose) + (International Contract Volumes x Contract Price)
- **Historical growth rate**: Highly negative (contracted from $18.4 billion in 2022 to roughly $1.5 billion in 2025).
- **Key growth levers and headwinds**: Headwinds include extreme pandemic fatigue and lower vaccination rates. Levers include price increases in the commercial market and potential combination vaccines (Flu/COVID).
- **Pricing dynamics**: Transitioned from government pandemic contracts ($15 to $25 per dose) to a commercial market pricing model ($110 to $130 list price, with significant gross-to-net discounts).
- **Revenue recognition notes**: Recognised upon delivery to the customer or channel partner.
- **Seasonality**: Extreme seasonality. Q3 and Q4 account for 75% to 85% of annual sales due to the autumn/winter respiratory vaccination season.

### Product Sales: mRESVIA (RSV)

- **Segment name**: Net Product Sales - mRESVIA
- **Revenue driver formula**: Addressable Older Adult Population x Vaccination Rate x Moderna Market Share x Net Price
- **Historical growth rate**: N/A (Launched in 2024).
- **Key growth levers and headwinds**: Headwinds include entrenched competition from GSK (Arexvy) and Pfizer (Abrysvo), and missed 2024 contracting cycles. Levers include pre-filled syringe convenience and label expansion to younger high-risk adults.
- **Pricing dynamics**: Competitive commercial pricing, heavily dependent on pharmacy benefit manager (PBM) and government contracting.
- **Seasonality**: Highly seasonal, mirroring the autumn respiratory market.

### Grant and Collaboration Revenue

- **Segment name**: Grant, Collaboration, and Licensing Revenue
- **Revenue driver formula**: Amortisation of upfront payments + Milestone achievements + Government grant drawdowns (e.g., BARDA).
- **Historical growth rate**: Lumpy and unpredictable, typically ranging from $100 million to $200 million annually.
- **Key growth levers and headwinds**: Driven by pipeline progress with partners like Merck (for the INT melanoma programme).

## Cost Structure



### Variable Costs / COGS

- **Line-by-line breakdown**: Raw materials, CMO manufacturing fees, internal manufacturing overhead, royalties, inventory write-downs, and unutilised capacity charges.
- **Gross margin range**: Historically 85% during peak COVID, recently compressed to 55% to 60% (COGS at 40% to 45% of sales) due to lower volumes and fixed overhead.
- **Key input costs**: Plasmids, lipids, and fill-finish CMO capacity.
- **How COGS scales**: Step-function. The company has high fixed manufacturing overhead. When volumes drop, unutilised capacity charges severely penalise gross margins.

### Operating Expenses

- **R&D**: Massive expense, running at $4.1 billion to $4.5 billion annually (over 200% of 2025 revenue). It covers discovery, preclinical, and massive Phase 3 global trials. Costs are expensed as incurred, not capitalised.
- **SG&A**: Approximately $1.1 billion to $1.2 billion. Driven by the global commercial footprint required to sell vaccines directly to pharmacies and governments.
- **Depreciation & Amortisation**: Embedded within COGS and operating expenses, scaling up as the company completes its internal manufacturing build-outs.
- **Stock-Based Compensation**: Significant, historically running at $400 million to $600 million annually, heavily impacting GAAP vs non-GAAP metrics.
- **Restructuring charges**: Material in 2024 and 2025 as the company resized its manufacturing footprint and reduced headcount to target a $4.9 billion total OpEx base for 2026.

### Margin Profile

- **Gross margin**: 55% to 60% currently, targeting 70%+ long-term.
- **Operating margin**: Deeply negative (operating loss of over $3 billion in 2024 and 2025).
- **Net margin**: Deeply negative, partially offset by substantial interest income on cash balances.

## Balance Sheet Structure

- **Total assets**: Approximately $14 billion to $16 billion.
- **Key asset categories**: Cash, cash equivalents, and short-term investments form the vast majority of assets (approximately $8.1 billion at year-end 2025).
- **Goodwill & intangibles**: Minimal. Moderna relies on organic R&D rather than M&A.
- **Working capital profile**:
  - **DSO**: 45 to 60 days, but spikes in Q4 due to autumn vaccine deliveries being collected in Q1 of the following year.
  - **DIO**: High (150+ days) due to the need to build inventory ahead of the autumn season, leading to frequent write-down risks.
  - **DPO**: 30 to 45 days.
  - **Net working capital**: Highly seasonal. The company uses cash to build inventory in H1 and collects receivables in Q4/Q1.
- **PP&E**: Growing significantly as the company builds out its Norwood campus and international mRNA manufacturing facilities.
- **Right-of-use assets**: Moderate, related to leased laboratory and office spaces in Cambridge and globally.

## Capital Expenditure & Investment

- **Capex as % of revenue**: Currently distorted by low revenue (running at $400 million in 2025, or ~20% of revenue).
- **Maintenance vs. growth**: Vast majority is growth capex (facility build-outs).
- **Major capex programmes**: Norwood campus expansion and new facilities in the UK, Canada, and Australia (often co-funded by local governments).
- **Capitalised software**: Minimal.
- **M&A pattern**: Organic grower. The company occasionally buys priority review vouchers (PRVs) or small bolt-on tech tuck-ins, but no transformational M&A.

## Debt & Capital Structure

- **Total debt**: Approximately $0.6 billion drawn from a recently announced $1.5 billion term loan facility.
- **Net debt**: Deeply negative (net cash position of ~$7.5 billion).
- **Credit rating**: Investment grade profile due to cash, though cash burn is a credit focus.
- **Key debt instruments**: Five-year term loan facility.
- **Interest rate profile**: Floating rate on the term loan; cash investments are in short-term government and corporate bonds yielding 4% to 5%.
- **Share repurchase programme**: Suspended. The company previously bought back shares during the COVID peak but is now preserving cash.
- **Dividend policy**: No dividend.

## Cash Flow Characteristics

- **Operating cash flow conversion**: Negative. The company is burning over $1.5 billion in operating cash flow annually.
- **Free cash flow margin**: Deeply negative.
- **Major non-cash items**: Stock-based compensation, depreciation, and massive inventory write-downs/unutilised capacity charges.
- **Working capital cash flow impact**: Massive swings. Q1 sees huge cash inflows from Q4 receivables collections; Q2/Q3 see cash outflows for inventory build.
- **Capex intensity**: Moderate absolute dollars ($400 million) but high relative to current depressed revenues.
- **Cash tax rate**: Effectively zero. The company is generating massive net operating losses (NOLs) which it is carrying forward.

## Sheet Structure

1. **Assumptions**: Hardcoded drivers for macro, pricing, market share, and pipeline probability of success (PoS).
2. **Scenarios**: Toggles for Base, Bull, and Bear cases (specifically flexing RSV market share and INT melanoma trial success).
3. **Epidemiology & Revenue**: Row-level build for Spikevax (US and ROW), mRESVIA (US and ROW), and risk-adjusted pipeline revenues (mRNA-1010 Flu, INT Melanoma, Rare Diseases).
4. **Income Statement**: GAAP format mirroring the 10-K. Product Sales, Other Revenue, Cost of Sales, R&D, SG&A, Interest Income, Interest Expense, Taxes.
5. **Balance Sheet**: Cash & Investments, Accounts Receivable, Inventory, PP&E, ROU Assets, Accounts Payable, Deferred Revenue, Debt, Retained Earnings.
6. **Cash Flow Statement**: Net Income, D&A, SBC, Inventory Write-downs, WC Changes, OCF, CapEx, Free Cash Flow, Debt Drawdowns.
7. **Working Capital & CapEx**: Schedules for DSO, DIO, DPO, and PP&E roll-forward.
8. **Debt & Interest**: Term loan schedule, interest expense calculation, and interest income calculation based on average cash balances.
9. **DCF Valuation**: Unlevered free cash flow, WACC calculation, terminal value, and implied share price.

## Key Financial Relationships

1. `Spikevax Revenue = (US Market Size x Moderna US Share x US Net Price) + (ROW Market Size x Moderna ROW Share x ROW Net Price)`
2. `mRESVIA Revenue = Total RSV Adult Market Doses x Moderna Market Share x Net Price`
3. `Pipeline Risk-Adjusted Revenue = Target Addressable Market x Peak Penetration % x Probability of Success (PoS)`
4. `Total Product Sales = Spikevax Revenue + mRESVIA Revenue + Commercialised Pipeline Revenue`
5. `Cost of Sales = Total Product Sales x Adjusted Gross Margin % + Unutilised Capacity Charges`
6. `Total Operating Expenses = Cost of Sales + R&D Expense + SG&A Expense`
7. `Operating Income = Total Revenue - Total Operating Expenses`
8. `Interest Income = Average(Beginning Cash & Investments, Ending Cash & Investments) x Average Yield on Cash`
9. `Net Income = Operating Income + Interest Income - Interest Expense - Taxes`
10. `Free Cash Flow = Net Income + D&A + SBC + Non-Cash Inventory Charges - Change in NWC - CapEx`
11. `Ending Cash Balance = Beginning Cash Balance + Free Cash Flow + Debt Drawdowns`

## Cross-Sheet Dependencies

The **Epidemiology & Revenue** sheet is the foundation. It feeds the top line of the **Income Statement**. The revenue seasonality dictates the Accounts Receivable and Inventory builds on the **Working Capital** sheet, which in turn drives the massive working capital adjustments on the **Cash Flow Statement**. The **Cash Flow Statement** determines the Ending Cash Balance on the **Balance Sheet**. The Ending Cash Balance feeds back into the **Debt & Interest** sheet to calculate Interest Income, which flows back into the **Income Statement**. This creates a circular reference between Cash, Interest Income, and Net Income, requiring a circuit breaker or iterative calculation toggle.

## Sign Convention

- **Income Statement**: Revenues are positive. Expenses (COGS, R&D, SG&A, Interest Expense) are positive numbers. Margins and subtotals subtract expenses from revenues.
- **Balance Sheet**: Assets are positive. Liabilities and Equity are positive. Total Assets must equal Total Liabilities + Equity.
- **Cash Flow Statement**: Net Income is the starting point. Cash inflows (e.g., increase in AP, decrease in AR) are positive. Cash outflows (e.g., CapEx, increase in Inventory, debt repayment) are negative.

## Things Most Likely to Go Wrong

1. **Interest Income Omission**: Moderna has ~$8.1 billion in cash. At a 4.5% yield, this generates over $350 million in interest income, which materially offsets operating cash burn. Failing to model this accurately breaks the cash runway analysis.
2. **Seasonality Mismatch**: Modelling revenue evenly across four quarters will break the working capital schedule. 75%+ of revenue occurs in Q3/Q4, meaning AR spikes at year-end and unwinds in Q1.
3. **Inventory Write-Downs**: The company frequently takes non-cash charges for expired vaccines. If these are not added back in the Cash Flow Statement, operating cash flow will be understated.
4. **Pipeline Probability Weighting**: Valuing the pipeline at 100% of peak sales will wildly overvalue the company. Phase 3 assets (like INT) must be probability-weighted (e.g., 60-70% PoS).
5. **R&D Scaling**: R&D does not scale down linearly with revenue. It is a fixed commitment to clinical trials. Modelling R&D as a standard % of revenue will result in massive errors; it must be modelled as an absolute dollar figure targeting management's $4.9 billion total OpEx guidance.
6. **Stock-Based Compensation**: SBC is a massive non-cash expense. Excluding it from valuation metrics flatters the company, but it must be added back to OCF while simultaneously increasing the diluted share count to capture shareholder dilution.
7. **Tax Rate Assumptions**: Applying a standard 21% statutory tax rate will penalise cash flows. The company has significant NOLs and currently guides to "negligible" cash taxes.
8. **Unutilised Capacity**: COGS is not purely variable. If revenue drops below a certain threshold, fixed CMO contracts trigger unutilised capacity charges, causing gross margins to plummet non-linearly.

## Validation Checks

1. "Total 2025 Revenue must equal approximately $1.9 billion as per management guidance."
2. "Total 2026 GAAP Operating Expenses (COGS + R&D + SG&A) must sum to approximately $4.9 billion."
3. "Year-end 2025 Cash & Investments must equal approximately $8.1 billion."
4. "Interest Income should be between $300 million and $400 million annually based on current cash balances and yields."
5. "Q3 and Q4 combined revenue must represent >75% of total annual product sales."
6. "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period."
7. "Cash balance must not drop below $0; if it does, the model must trigger a debt drawdown or flag a liquidity shortfall."
8. "Effective cash tax rate should remain near 0% until cumulative future net income exhausts historical NOLs."

## Key Assumptions (Default Values)

| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| 2025 Total Revenue | 1,900 | $ Millions | Actual unaudited guidance provided at JPM 2026. |
| 2026 Revenue Growth | 10.0 | % | Management guidance of "up to 10%" growth for 2026. |
| 2026 R&D Expense | 3,800 | $ Millions | Estimated portion of the $4.9B total OpEx target. |
| 2026 SG&A Expense | 1,100 | $ Millions | Estimated portion of the $4.9B total OpEx target. |
| Cost of Sales Margin | 40.0 | % of Sales | Normalised rate excluding major resizing charges, based on recent quarters. |
| Cash Yield | 4.5 | % | Blended yield on short-term government and corporate securities. |
| Term Loan Interest Rate | 6.0 | % | Estimated floating rate on the $1.5B facility. |
| Q3/Q4 Revenue Weighting | 80.0 | % | Historical seasonality for respiratory vaccine deliveries. |
| Days Sales Outstanding (DSO) | 55 | Days | Based on historical Q4 receivables spikes. |
| Days Inventory Outstanding (DIO) | 180 | Days | High inventory requirements for seasonal vaccine builds. |
| CapEx | 400 | $ Millions | 2025 guidance, assumed flat for near-term facility completion. |
| Effective Tax Rate | 0.0 | % | Management guidance of negligible taxes due to NOLs. |
| Diluted Share Count | 385 | Millions | Recent 10-Q diluted share count. |
| WACC | 10.5 | % | High beta biotech profile with pipeline execution risk. |
| Terminal Growth Rate | 2.0 | % | Standard long-term pharmaceutical growth rate. |

## Data Sources & Benchmarks

- **SEC EDGAR**: Moderna (MRNA) 10-K, 10-Q, and 8-K filings.
- **Investor Relations**: Moderna Q4 2025 Earnings Presentation and J.P. Morgan Healthcare Conference 2026 update slides.
- **Key Peers**: BioNTech (BNTX) for mRNA platform benchmarking; GSK (GSK) and Pfizer (PFE) for RSV and respiratory market share benchmarking.
- **Industry Data**: CDC FluView and RSV-NET for US vaccination rates and epidemiology data.
- **Consensus Estimates**: FactSet or Bloomberg for street expectations on pipeline PoS and peak sales.

## Sources

- Moderna Inc. Q3 2025 Earnings Release and Call Transcript (November 2025).
- Moderna Inc. Business Update at the 44th Annual J.P. Morgan Healthcare Conference (January 12, 2026).
- Moderna Inc. Q4 2025 Earnings Call Transcript and Press Release (February 13, 2026).
- SEC EDGAR Database (Moderna 2024 10-K and 2025 10-Qs).

---

## Frequently asked questions

### What is Moderna's primary business focus?

Moderna is a pioneering biotechnology company that develops messenger RNA (mRNA) therapeutics and vaccines. While historically known for its COVID-19 vaccine, Spikevax, the company is currently transitioning into a broader respiratory and oncology business.

### What are the main revenue streams for Moderna?

Moderna's revenue streams primarily consist of Product Sales, which include its COVID-19 vaccine (Spikevax) and the newly launched RSV vaccine (mRESVIA). The company also generates revenue from Grant and Collaboration agreements.

### How does Moderna's capital expenditure strategy impact its financial model?

Moderna's capital expenditure is predominantly growth-oriented, focusing on significant facility build-outs like the Norwood campus and new international manufacturing sites. The financial model assumes Capex as a percentage of revenue at approximately 15.15%, reflecting these substantial investments despite current lower revenue levels.

### What is the main objective of the Moderna financial model?

The primary objective of the Moderna financial model is to evaluate the company's cash runway and equity valuation. It aims to determine if Moderna can successfully achieve its stated 2028 cash-flow breakeven target without requiring highly dilutive equity financing.

### Can I download an Excel financial model for Moderna?

Yes, a downloadable Excel financial model for Moderna is available. This model provides a forecast horizon from FY2026 through FY2030, allowing for detailed analysis of the company's future financial performance.

### What are the key assumptions regarding Moderna's operating expenses in the financial model?

The financial model incorporates key assumptions for operating expenses, such as Research & Development (R&D) at 35% of revenue and Selling, General & Administrative (SGA) expenses at approximately 47.66% of revenue. These percentages reflect Moderna's ongoing investment in pipeline development and market presence.

[Interactive forecast calculator](https://finamodel.com/companies/moderna/forecast)